Separately, Kepler Capital Markets upgraded shares of DBV Technologies from a hold rating to a buy rating and set a €6.00 ($6.12) price objective on the stock in a report on Thursday, August 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, DBV Technologies has a consensus rating of Hold and an average target price of $5.63.
DBV Technologies Price Performance
NASDAQ DBVT opened at $1.38 on Tuesday. DBV Technologies has a 12 month low of $1.15 and a 12 month high of $3.43. The stock has a market capitalization of $259.51 million, a P/E ratio of -2.51 and a beta of 1.43. The firm’s 50-day moving average is $1.65 and its two-hundred day moving average is $1.98.
Institutional Inflows and Outflows
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.